Allergen-specific immunotherapy: is it vaccination against toxins after all?

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 72, Issue 1, 2017, Pages 13-23

  Bachmann, M F ^a,b   Kundig T M ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

allergen; IgG; protection

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PROTOXIN; ANTIBODY; IMMUNOGLOBULIN E; TOXIN;

ALLERGIC REACTION; ALLERGY; B LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA VACCINATION; PATHOGENESIS; POLLEN ALLERGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; VACCINATION; ANIMAL; DESENSITIZATION; GENE REARRANGEMENT; HYPERSENSITIVITY; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PROCEDURES; SUBLINGUAL IMMUNOTHERAPY; TREATMENT OUTCOME;

ALLERGENS; ANIMALS; ANTIBODIES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOMODULATION; SUBLINGUAL IMMUNOTHERAPY; T-LYMPHOCYTES, REGULATORY; TOXINS, BIOLOGICAL; TREATMENT OUTCOME; VACCINATION;

EID: 84992462835     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12890     Document Type: Review

References (120)

1. Bostock J. Case of a periodical affection of the eyes and chest. Med Chir Trans 1819;10:161–165.
2. Blackley CH. Experimental researches on the causes and nature of catarrhus aestivus (hay fever or hay asthma). London: Bailliere, Tindall & Cox; 1873.
3. Curtis HH. The immunizing cure of hay fever. NY Med J 1900;77:16–18.
4. Besredka A. Du mechanisme de l'anaphylaxie vis-a-vis de serum de chaval. CR Soc Biol 1907;59:294–296.
5. Besredka A. Comment empecher l'anaphylaxie? CR Soc Biol 1907;59:1053.
6. Dunbar WP. Zur Ursache und spec. Heil. des Heufiebers. Dtsch Med Wochenschr 1903;9:24–28.
7. Dunbar WP. Zur Frage betreffend der spezifischen Heilung des Heufiebers. Berl Klin Wochenschrift 1903;40:569.
8. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;177:1572–1573.
9. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911;178:814–817.
10. Jackson M. John Freeman, hay fever and the origins of clinical allergy in Britain 1900–1950. Stud Hist Philos Biol Biomed Sci 2003;34:473–490.
11. Elliotson J. On hay fever. Lancet 1830;ii:370–373.
12. Bostock J. Of the catarrhus aestivus, or summer catarrh. Med Chir Trans 1828;14:437–446.
13. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733–743.
14. Warner JO. Obesity and allergic disease: closely related epidemics of the 21st century. Pediatr Allergy Immunol 2009;20:305–306.
15. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259–1260.
16. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrländer C et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364:701–709.
17. Harb H, Renz H. Update on epigenetics in allergic disease. J Allergy Clin Immunol 2015;135:15–24.
18. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol 2016;137:358–368.
19. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 2015;136:556–568.
20. Pajno GB, Barberi S. The history of sublingual immunotherapy. Int J Immunopathol Pharmacol 2009;22:1–3.
21. Eichenberger H, Storck H. Co-seasonal desensitization of pollinosis with the scarification-method of Blamoutier. Acta Allergol 1966;21:261–267.
22. Vallery-Radot P, Hangenau J. Asthme d'origine équine. Essai de désensibilisation par des cutiréactions répétées. Bull Soc Méd Hôp Paris 1921;45:1251–1260.
23. Blamoutier P, Blamoutier J, Guibert L. Traitement co-saisonnier de la pollinose par l'application d'extraits de pollens sur des quadrillages cutanés: Résultats obtenus en 1959 et 1960. Revue Française d'Allergie 1:112–120.
24. Phillips EW. Relief of hay-fever by intradermal injections of pollen extract. J Am Med Assoc 1926;86:182–184.
25. Senti G, Graf N, Haug S, Rüedi N, von Moos S, Sonderegger T et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997–1002.
26. Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011;66:798–809.
27. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, Kündig TM. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129:128–135.
28. von Moos S, Johansen P, Tay F, Graf N, Kündig TM, Senti G. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. J Allergy Clin Immunol 2014;134:965–967.
29. Senti G, von Moos S, Tay F, Graf N, Johansen P, Kündig TM. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015;70:707–710.
30. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908–17912.
31. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol 2013;131:412–420.
32. Patterson AM, Bonny AE, Shiels WE II, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol 2015;116:168–170.
33. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013;132:1248–1252.
34. Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol 2014;133:930–931.
35. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129:1290–1296.
36. Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB et al. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy 2014;69:1162–1170.
37. Hylander T, Larsson O, Petersson-Westin U, Eriksson M, Kumlien Georén S, Winqvist O, Cardell LO. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res 2016;17:10.
38. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021–1035.
39. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 2009;64(Suppl 91):1–59.
40. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013;132:353–360.
41. Canonica GW, Cox L, Pawankar R, Baena-Cagnan EC, Blaiss M, Bonini S et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:265–272.
42. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66:740–752.
43. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 2016;137:339–349.
44. Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint. J Allergy Clin Immunol 2010;126:668–669.
45. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med 2015;175:1301–1309.
46. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–475.
47. Von Pirquet C. Allergie. Munch Med Wochenschr 1906;53:1457;1–415.
48. Tardieu de Maleissye J. Histoire du poison. Paris: F. Bourin; 1991.
49. Clementsen P, Douglas AR, Skehel JJ, Hannoun C, Bach-Mortensen N, Norn S. Influenza A virus enhances IgE-mediated histamine release from human basophil leukocytes. Examination of the effect of viral neuraminidase and haemagglutinin. Agents Actions 1989;27:58–61.
50. Clementsen P, Norn S, Kristensen KS, Hannoun C. Influenza A virus enhances basophil histamine release and the enhancement is abolished by carbohydrates. Allergy 1990;45:471–476.
51. Smith-Norowitz TA, Wong D, Kusonruksa M, Norowitz KB, Joks R, Durkin HG, Bluth MH. Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. Int J Med Sci 2011;8:239–244.
52. Grunewald SM, Hahn C, Wohlleben G, Teufel M, Major T, Moll H, Bröcker EB, Erb KJ. Infection with influenza a virus leads to flu antigen-induced cutaneous anaphylaxis in mice. J Invest Dermatol 2002;118:645–651.
53. Davidsson A, Eriksson JC, Rudblad S, Brokstad KA. Influenza specific serum IgE is present in non-allergic subjects. Scand J Immunol 2005;62:560–561.
54. Lindenmann J. Origin of the terms ‘antibody’ and ‘antigen’. Scand J Immunol 1984;19:281–285.
55. Cooke RA, Barnard JH, Hebald S, Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever). J Exp Med 1935;62:733–750.
56. Ishizaka K, Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 1967;99:1187–1198.
57. Johansson SG, Bennich H, Wide L. A new class of immunoglobulin in human serum. Immunology 1968;14:265–272.
58. Gershon RK. A disquisition on suppressor T cells. Transplant Rev 1975;26:170–185.
59. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213–1219.
60. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–173.
61. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644–651.
62. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187–4194.
63. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:1356–1365.
64. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131–1139.
65. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradley KL et al. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells. J Allergy Clin Immunol 1997;99:530–538.
66. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–1164.
67. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Müller U, Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676–1683.
68. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98–106.
69. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255–1261.
70. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608–615.
71. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205–1214.
72. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007;7:875–888.
73. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 2006;203:777–788.
74. Yu XL, Cheng YM, Shi BS, Qian FX, Wang FB, Liu XN et al. Measles virus infection in adults induces production of IL-10 and is associated with increased CD4+ CD25+ regulatory T cells. J Immunol 2008;181:7356–7366.
75. Piersma SJ, van der Hulst JM, Kwappenberg KM, Goedemans R, van der Minne CE, van der Burg SH. Influenza matrix 1-specific human CD4+ FOXP3+ and FOXP3(−) regulatory T cells can be detected long after viral clearance. Eur J Immunol 2010;40:3064–3074.
76. Zhao J, Fett C, Trandem K, Fleming E, Perlman S. IFN-{gamma}- and IL-10-expressing virus epitope-specific Foxp3+ T reg cells in the central nervous system during encephalomyelitis. J Exp Med 2011;208:1571–1577.
77. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472–482.
78. Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch H, Michel FB. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy 1986;56:456–459.
79. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982;70:261–271.
80. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001;357:752–756.
81. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008;63:1455–1463.
82. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008;4:e1000138.
83. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999;103:326–332.
84. Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978;61:370–377.
85. Schmitz N1, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009;206:1941–1955.
86. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127:S1–S55.
87. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012;18:673–683.
88. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009;8:645–660.
89. Loveless MH. Immunological studies of pollinosis. I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay fever patients. J Immunol 1940;38:25–50.
90. Loveless MH. Immunological studies of pollinosis. IV. The relationship between thermostable antibody in the circulation and clinical immunity. J Immunol 1943;47:165–180.
91. Lichtenstein LM, Holtzman NA, Burnett LS. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101:317–324.
92. Tada T, Okumura K. Regulation of homocytotropic antibody formation in the rat. I. Feed-back regulation by passively administered antibody. J Immunol 1971;106:1002–1011.
93. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004;4:313–318.
94. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004;113:1025–1034.
95. Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy 1993;23:647–660.
96. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;17:459–468.
97. Visco V, Dolecek C, Denépoux S, Le Mao J, Guret C, Rousset F, Guinnepain MT et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996;157:956–962.
98. Denépoux S1, Eibensteiner PB, Steinberger P, Vrtala S, Visco V, Weyer A et al. Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett 2000;465:39–46.
99. Jakobsen CG, Bodtger U, Kristensen P, Poulsen LK, Roggen EL. Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and Humicola lanuginosa lipase from combinatorial phage libraries. Mol Immunol 2004;41:941–953.
100. Jakobsen CG, Bodtger U, Poulsen LK, Roggen EL. Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance. Clin Exp Allergy 2005;35:193–198.
101. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915–922.
102. Kemeny DM, MacKenzie-Mills M, Harries MG, Youlten LJ, Lessof MH. Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens. J Allergy Clin Immunol 1983;72:376–385.
103. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983;130:722–726.
104. Aalberse RC, Schuurman J. IgG4 as a blocking antibody. Clin Rev Allergy 1983;1:289–302.
105. Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999;29:497–506.
106. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999;29:2026–2036.
107. Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D, Valenta R. B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999;13:1277–1290.
108. Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470–1476.
109. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007;178:2415–2420.
110. Bessa J, Jegerlehner A, Hinton HJ, Pumpens P, Saudan P, Schneider P, Bachmann MF. Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol 2009;183:3788–3799.
111. Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L et al. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 2011;34:375–384.
112. Uermösi C, Beerli RR, Bauer M, Manolova V, Dietmeier K, Buser RB et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010;126:375–383.
113. Flicker S, Gadermaier E, Madritsch C, Valenta R. Passive immunization with allergen-specific antibodies. Curr Top Microbiol Immunol 2011;352:141–159.
114. DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32:239–247.
115. Creticos PS1, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445–1455.
116. Rosewich M, Lee D, Zielen S. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Hum Vaccin Immunother 2013;9:1523–1531.
117. Yoshida K, Matsuoka M, Usuda S, Mori A, Ishizaka K, Sakano H. Immunoglobulin switch circular DNA in the mouse infected with Nippostrongylus brasiliensis: evidence for successive class switching from mu to epsilon via gamma 1. Proc Natl Acad Sci U S A 1990;87:7829–7833.
118. Martínez Gómez JM, Fischer S, Csaba N, Kündig TM, Merkle HP, Gander B, Johansen P. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res 2007;24:1927–1935.
119. Thunberg S, Neimert-Andersson T, Cheng Q, Wermeling F, Bergström U, Swedin L et al. Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice. Allergy 2009;64:919–926.
120. Marsh DG, Lichtenstein LM, Campbell DH. Studies on “allergoids” prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970;18:705–722.